Demographic and clinical characteristics of patients with definite, probable and possible tuberculous meningitis (TBM).

IQR, interquartile range; n, number of patients; N, total number of patients for whom results were available; HIV, human immunodeficiency virus; ART, antiretroviral therapy; TB, tuberculosis; LP, lumbar puncture; D4T, stavudine 30 mg twice daily; 3TC, lamivudine 150 mg twice daily or 300 mg daily; EFV, efavirenz 600 mg nightly; AZT, zidovudine 300 mg twice daily; NEV, nevirapine 200 mg twice daily; ddI, didanosine 400 mg daily; LPV/rtv, lopinavir/ritonavir 800/200 mg twice daily.
*Significantly different (p<0.05) from patients with definite TBM;
**p<0.01.
1Only performed in HIV-infected patients.
2N includes HIV-infected patients only. Treatment regimens included: 1) D4T, 3TC, EFV (n = 11), 2) AZT, 3TC, NEV (n = 3), 3) D4T, 3TC, NEV (n = 3), 4) AZT, 3TC, EFV (n = 1), 5) AZT, 3TC, LPV/rtv (n = 1), 6) AZT, ddI, LPV/rtv (n = 1).
3Refers to symptoms reported by patient or family only.
4British Medical Research Council TBM disease grades: 1- Glasgow coma scale (GCS) 15 with no neurological deficit; 2- GCS 11–14 without neurological deficit, or GCS 15 with focal neurological deficit; 3- GCS≤10.15
5Refers to clinical findings on physical examination only.